Industry Pipeline

February 2011
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p30
Academic Journal
The article offers news briefs related to pharmaceutical industry in the U.S. including Advanced Cell Technology Inc.'s MA09-hRPE drug which was granted an orphan drug designation by the Food and Drug Administration (FDA), FDA's approval of the Zymaxid anti-infective drug from Allergan Inc., and EyeGate Pharma Inc.'s phase three study for dry eye syndrome treatment.


Related Articles

  • Theragenics begins dosing study with FDA OK.  // Ophthalmology Times;9/1/2004, Vol. 29 Issue 17, p32 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) on Theragenics Corp.'s TheraSight ocular brachytherapy system for the treatment of age-related macular degeneration. Grant of the FDA to Theragenics Corp. on an investigational device exemption to begin patient study;...

  • Multi-pronged approach limits endophthalmitis risk. Guttman, Cheryl // Ophthalmology Times;3/15/2007, Vol. 32 Issue 6, p13 

    The article reports on the risk of endophthalmitis, in which further research is required for designing optimal strategies. This is what Dr. Samuel Masket, clinical professor of ophthalmology, during the annual meeting of the American Academy of Ophthalmology. He explains that studies should be...

  • Industry Pipeline.  // Ocular Surgery News;10/25/2014, Vol. 32 Issue 20, p34 

    The article covers issues related to ophthalmology as of October 2014. Dexamethasone intravitreal implant Ozurdex was approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic macular edema. Eylea aflibercept injection was approved by the European Commission for the...

  • ACRO Testifies Before FDA on Clinical Trial Modernization.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article offers information on recommendations made by the Association of Clinical Research Organizations (ACRO) in order to assist the U.S. Food and Drug Administration in improving drug development process. Doug Peddicord, Director of ACRO, states that the current drug development system is...

  • ISTA Files NDA for Bepreve.  // Review of Ophthalmology;Dec2008 Part 1 of 2, Vol. 15 Issue 12, p7 

    The article reports on the move of Ista Pharmaceuticals to file a New Drug Application with the U.S. Food and Drug Administration (FDA) for the approval of its Bepreve (bepotastine ophthalmic solution), an eyedrop treatment used for ocular itching associated with allergic conjunctivitis. In the...

  • FDA Briefs.  // Ophthalmology Times;4/1/2004, Vol. 29 Issue 7, p12 

    Focuses on news items about approval of ophthalmic procedures by the U.S. Food and Drug Administration. Clearance of a glaucoma treatment from NeoMedix Corp.; Evaluation of the laser microkeratome from German manufacturer Perfect Vision.

  • Industry Pipeline.  // Ocular Surgery News;7/25/2014, Vol. 32 Issue 14, p30 

    The article offers information on clinical trials of ophthalmic medicines as of July 2014. The topics discussed include FDA approval for Ozurdex, a dexamethasone intravitreal implant from pharmaceutical firm Allergan, resubmission of a new drug application to U.S. FDA for lluvien, a fluocinolone...

  • Industry Pipeline.  // Ocular Surgery News;10/25/2012, Vol. 30 Issue 20, p42 

    The article announces recent approvals, research applications and study initiation in the ophthalmic industry including FDA's approval of Eylea for macular edema by Regeneron, new drug application for Prolensa by Bausch & Lomb and Amakem's phase 2 study of its rho-kinase inhibitor AMA0076.

  • FDA moves faster than EMA: study. Dickson, James G. // Medical Marketing & Media;Aug2012, Vol. 47 Issue 8, p26 

    The article reports on the study "New England Journal of Medicine," which indicates that the review process of U.S. Food and Drug Administration is faster than those in other countries


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics